Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight strong remission and response rates and offer insights into improving treatment options for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and acute myeloid leukemia (AML) in older or chemotherapy-ineligible patients. ‘Novel CAR T cell therapy obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL’ The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell Read More

Related posts:

  1. Novel radiotracer rapidly detects gastrointestinal cancer biomarker, identifies patients for targeted therapy
  2. Patients receiving exceptions to participate in targeted therapy trial have similar outcomes to eligible participants
  3. New combination therapy shows promise for bladder cancer patients unresponsive to standard treatment
  4. New Co-STAR T cells show promise for treating cancers in laboratory study
  5. Models show promise in predicting cognitive decline in early Alzheimer’s
  6. FAP-targeted therapy demonstrates significant efficacy in controlling advanced sarcomas
  7. Genetically healthy skin transplants show promise for rare skin disorders
  8. Stem cell-derived therapy shows promise against treatment-resistant liver cancer

Leave a Reply

Your email address will not be published. Required fields are marked *